BACKGROUND: The increasing morbidity of liver cancer has led to a growing demand for transplantation. Split liver transplantation(SLT) is a promising way to ameliorate organ shortages. However, the safety and efficacy...BACKGROUND: The increasing morbidity of liver cancer has led to a growing demand for transplantation. Split liver transplantation(SLT) is a promising way to ameliorate organ shortages. However, the safety and efficacy of SLT are still controversial. The aim of this study was to assess the clinical outcome of SLT in liver cancer patients at our center. METHODS: A total of 74 patients who received liver transplantation at a tertiary hospital from March 2019 to July 2023 were retrospectively studied, of whom 37 recipients underwent SLT and 37 recipients underwent whole-graft liver transplantation(WGLT). Clinical data were analyzed and compared between patients who underwent SLT and WGLT.RESULTS: SLT and WGLT were successfully performed, with no intraoperative transplantrelated mortality. Postoperatively, no significant differences in total bilirubin(TB, P=0.266), alanine transaminase(ALT, P=0.403) and aspartate transaminase(AST, P=0.160) levels within 30 d were detected between the two groups. The transplant-related mortality rates were 8.1% in the SLT group and 5.4% in the WGLT group within 30 d of surgery(P=1.000), and 10.8% and 8.1%, respectively, at 90 d after surgery(P=1.000). There were no significant differences in overall survival(OS) and progress-free survival(PFS) between the SLT and WGLT groups(P=0.910, P=0.190). CONCLUSION: Our results show that SLT does not imply additional risks in treating liver cancer compared with WGLT.展开更多
Prostate cancer(PC)is an epithelial malignancy occurring in the prostate.PC ranks second in incidence among all male malignancies globally by the latest statistics from the World Health Organization.Notably,China has ...Prostate cancer(PC)is an epithelial malignancy occurring in the prostate.PC ranks second in incidence among all male malignancies globally by the latest statistics from the World Health Organization.Notably,China has seen a more rapid increase in PC incidence compared to developed European and American nations.By 2022,the newly reported cases and deaths due to PC in China increased to 134,200 and 47,500,respectively.Thus,early diagnosis and stand-ardized treatment for prostate cancer in China remain far-reaching objectives.Burgeoning research on advanced PC and castration-resistant prostate cancer in recent years have paved the way for a new era of integrated treatment methods including novel endocrine drugs,chemotherapy,targeted therapy,and immunotherapy.Future therapies involve precision treatment guided by genetic testing and individualized integrated treatment as part of a multi-disciplinary integrated diagnosis and treatment model for PC.The Genitourinary Oncology Committee of theCACA guidelines for holistic integrative management of prostate cancer China Anti-Cancer Association(CACA-GU)has invited multidisciplinary experts across fields including surgery,oncology,pathology,radiology,herbal medicine,physiatry,and psychology to collaboratively write,discuss,and revise guide-lines on managing PC.The CACA Guidelines for Holistic Integrative Management of Prostate Cancer includes epide-miology,screening and diagnosis,treatment for localized PC,diagnosis and treatment of PC recurrence after radical prostatectomy,management of metastatic PC,traditional Chinese medicine diagnosis and treatment of PC,and reha-bilitation from PC.This guideline aims to standardize the clinical diagnosis and treatment management of PC in China.It is more aligned with China’s clinical practice,highlights Chinese characteristics,and bears significant clinical importance.展开更多
tRNA-derived small RNAs(tsRNAs)are novel non-coding RNAs that are involved in the occurrence and progression of diverse diseases.However,their exact presence and function in hepatocellular carcinoma(HCC)remain unclear...tRNA-derived small RNAs(tsRNAs)are novel non-coding RNAs that are involved in the occurrence and progression of diverse diseases.However,their exact presence and function in hepatocellular carcinoma(HCC)remain unclear.Here,differentially expressed tsRNAs in HCC were profiled.A novel tsRNA,tRNAGln-TTG derived 5′-tiRNA-Gln,is significantly downregulated,and its expression level is correlated with progression in patients.In HCC cells,5′-tiRNA-Gln overexpression impaired the proliferation,migration,and invasion in vitro and in vivo,while 5′-tiRNA-Gln knockdown yielded opposite results.5′-tiRNA-Gln exerted its function by binding eukaryotic initiation factor 4A-I(EIF4A1),which unwinds complex RNA secondary structures during translation initiation,causing the partial inhibition of translation.The suppressed downregulated proteins include ARAF,MEK1/2 and STAT3,causing the impaired signaling pathway related to HCC progression.Furthermore,based on the construction of a mutant 5′-tiRNA-Gln,the sequence of forming intramolecular G-quadruplex structure is crucial for 5′-tiRNA-Gln to strongly bind EIF4A1 and repress translation.Clinically,5′-tiRNA-Gln expression level is negatively correlated with ARAF,MEK1/2,and STAT3 in HCC tissues.Collectively,these findings reveal that 5′-tiRNA-Gln interacts with EIF4A1 to reduce related mRNA binding through the intramolecular Gquadruplex structure,and this process partially inhibits translation and HCC progression.展开更多
Background and Aims:For high morbidity and mortality,hepatocellular carcinoma(HCC)becomes a major health issue worldwide.Nowadays,numerous non-coding RNAs(ncRNAs)are known to regulate the occurrence and patho-genesis ...Background and Aims:For high morbidity and mortality,hepatocellular carcinoma(HCC)becomes a major health issue worldwide.Nowadays,numerous non-coding RNAs(ncRNAs)are known to regulate the occurrence and patho-genesis of tumors.Some ncRNAs have also been developed as tumor biomarkers and therapeutic targets.However,the potential function of the small Cajal body-specific RNA(scaRNA)SCARNA16,a newly identified ncRNA,remains to be explored in HCC.Methods:In both HCC cell lines and specimens from 120 enrolled patients,the expression val-ues of SCARNA16 were detected.We divided patients into SCARNA16 high and low expression subgroups,and then analyzed the difference of various clinical characteristics and prognosis data between subgroups.Results:Compared to paired controls,SCARNA16 was significantly down-regulated in HCC cell lines and clinical specimens(p<0.01).Besides,HCC patients with lower SCARNA16 expression commonly presented with larger and more tumor lesions,more ves-sel carcinoma emboli,more capsular invasion and higher TNM stages(p<0.05).Moreover,SCARNA16 expression was negatively correlated with postoperative prognosis of HCC patients in 5-year follow-up,including tumor-free survival(TFS)(median time of low vs.high subgroups:14 vs.48 months,p=0.006)and overall survival(OS)(median time of low vs.high subgroups:39 vs.52 months,p=0.001).Besides,SCARNA16 acted as an independent prognostic bio-marker in TFS(hazard ratio[HR]:0.578,95%CI:0.345-0.969,p=0.038)and OS(HR:0.366,95%CI:0.178-0.752,p=0.006).Conclusions:Low expression patterns of SCAR-NA16 remarkably associated with severe clinical status and poor survival of patients,suggesting that SCARNA16 pos-sesses potency as a novel biomarker for HCC.展开更多
The intricate tumor microenvironment presents formidable obstacles to the efficacy of adoptive T cell therapy in the management of solid tumors by limiting the infiltration and inducing exhaustion of the transferred T...The intricate tumor microenvironment presents formidable obstacles to the efficacy of adoptive T cell therapy in the management of solid tumors by limiting the infiltration and inducing exhaustion of the transferred T cells.Here,we developed a bacterial-based adjuvant approach that augments the efficacy of adoptive T-cell therapy for solid tumor treatment.Our study reveals that intratumor injection of E.coli MG1655 normalizes tumor vasculatures and reprograms tumor-associated macrophages into M1 phenotype that produce abundant CCL5,together facilitating tumor infiltration of adoptively transferred T cells.The depletion of tumor-associated macrophages or CCL5 neutralization in vivo leads to the significantly decreased solid tumor infiltration of adoptive T cells in the presence of bacteriotherapy.This combinatorial therapy,consisting of E.coli adjuvant and adoptive T-cell therapy,effectively eradicates early-stage melanoma and inhibits the progression of pancreatic tumors.Notably,this dual strategy also strengthened the distal tumor control capabilities of adoptive T-cell therapy through the induction of in situ tumor vaccination.This dual therapeutic approach involving bacterial therapy targeting the interior of solid tumors and adoptive T-cell therapy attacking the tumor periphery exhibits potent therapeutic efficacy in achieving the eradication of advanced-stage tumors,including melanoma and hepatocellular carcinoma,by converging attacks from both inside and outside the tumor tissues.展开更多
基金Key Project of Traditional Chinese Medicine Science and Technology Plan of Zhejiang Province (GZY-ZJ-KJ-24077)National Natural Science Foundation of China (No. U23A202181, 8207101520, 82272860)+2 种基金Central Guidance on Local Science and Technology Development Fund of Zhejiang Province (2023ZY1017)Fundamental Research Funds for the Central Universities (No. 226-2023-00038)Special Financial Support for Zhejiang Traditional Chinese Medicine Innovation Teams。
文摘BACKGROUND: The increasing morbidity of liver cancer has led to a growing demand for transplantation. Split liver transplantation(SLT) is a promising way to ameliorate organ shortages. However, the safety and efficacy of SLT are still controversial. The aim of this study was to assess the clinical outcome of SLT in liver cancer patients at our center. METHODS: A total of 74 patients who received liver transplantation at a tertiary hospital from March 2019 to July 2023 were retrospectively studied, of whom 37 recipients underwent SLT and 37 recipients underwent whole-graft liver transplantation(WGLT). Clinical data were analyzed and compared between patients who underwent SLT and WGLT.RESULTS: SLT and WGLT were successfully performed, with no intraoperative transplantrelated mortality. Postoperatively, no significant differences in total bilirubin(TB, P=0.266), alanine transaminase(ALT, P=0.403) and aspartate transaminase(AST, P=0.160) levels within 30 d were detected between the two groups. The transplant-related mortality rates were 8.1% in the SLT group and 5.4% in the WGLT group within 30 d of surgery(P=1.000), and 10.8% and 8.1%, respectively, at 90 d after surgery(P=1.000). There were no significant differences in overall survival(OS) and progress-free survival(PFS) between the SLT and WGLT groups(P=0.910, P=0.190). CONCLUSION: Our results show that SLT does not imply additional risks in treating liver cancer compared with WGLT.
基金supported by China Anti-Cancer Association(CACA).
文摘Prostate cancer(PC)is an epithelial malignancy occurring in the prostate.PC ranks second in incidence among all male malignancies globally by the latest statistics from the World Health Organization.Notably,China has seen a more rapid increase in PC incidence compared to developed European and American nations.By 2022,the newly reported cases and deaths due to PC in China increased to 134,200 and 47,500,respectively.Thus,early diagnosis and stand-ardized treatment for prostate cancer in China remain far-reaching objectives.Burgeoning research on advanced PC and castration-resistant prostate cancer in recent years have paved the way for a new era of integrated treatment methods including novel endocrine drugs,chemotherapy,targeted therapy,and immunotherapy.Future therapies involve precision treatment guided by genetic testing and individualized integrated treatment as part of a multi-disciplinary integrated diagnosis and treatment model for PC.The Genitourinary Oncology Committee of theCACA guidelines for holistic integrative management of prostate cancer China Anti-Cancer Association(CACA-GU)has invited multidisciplinary experts across fields including surgery,oncology,pathology,radiology,herbal medicine,physiatry,and psychology to collaboratively write,discuss,and revise guide-lines on managing PC.The CACA Guidelines for Holistic Integrative Management of Prostate Cancer includes epide-miology,screening and diagnosis,treatment for localized PC,diagnosis and treatment of PC recurrence after radical prostatectomy,management of metastatic PC,traditional Chinese medicine diagnosis and treatment of PC,and reha-bilitation from PC.This guideline aims to standardize the clinical diagnosis and treatment management of PC in China.It is more aligned with China’s clinical practice,highlights Chinese characteristics,and bears significant clinical importance.
基金generously supported by the National Natural Science Foundation of China(Nos.82072650 and 81902405)Key Research and Development Program of Zhejiang Province(No.2021C03121)+1 种基金2019 Liver Cancer Diagnosis and Treatment Communication Fund(No.CXPJJH11900009-12)Grant from Health Commission of Zhejiang Province(No.JBZX-202004).
文摘tRNA-derived small RNAs(tsRNAs)are novel non-coding RNAs that are involved in the occurrence and progression of diverse diseases.However,their exact presence and function in hepatocellular carcinoma(HCC)remain unclear.Here,differentially expressed tsRNAs in HCC were profiled.A novel tsRNA,tRNAGln-TTG derived 5′-tiRNA-Gln,is significantly downregulated,and its expression level is correlated with progression in patients.In HCC cells,5′-tiRNA-Gln overexpression impaired the proliferation,migration,and invasion in vitro and in vivo,while 5′-tiRNA-Gln knockdown yielded opposite results.5′-tiRNA-Gln exerted its function by binding eukaryotic initiation factor 4A-I(EIF4A1),which unwinds complex RNA secondary structures during translation initiation,causing the partial inhibition of translation.The suppressed downregulated proteins include ARAF,MEK1/2 and STAT3,causing the impaired signaling pathway related to HCC progression.Furthermore,based on the construction of a mutant 5′-tiRNA-Gln,the sequence of forming intramolecular G-quadruplex structure is crucial for 5′-tiRNA-Gln to strongly bind EIF4A1 and repress translation.Clinically,5′-tiRNA-Gln expression level is negatively correlated with ARAF,MEK1/2,and STAT3 in HCC tissues.Collectively,these findings reveal that 5′-tiRNA-Gln interacts with EIF4A1 to reduce related mRNA binding through the intramolecular Gquadruplex structure,and this process partially inhibits translation and HCC progression.
基金This study was supported by the National Natural Science Foundation of China(Nos.81773096 and 82072650)Key Research and Development Program of Zhejiang Province(Nos.2018C03085 and 2021C03121).
文摘Background and Aims:For high morbidity and mortality,hepatocellular carcinoma(HCC)becomes a major health issue worldwide.Nowadays,numerous non-coding RNAs(ncRNAs)are known to regulate the occurrence and patho-genesis of tumors.Some ncRNAs have also been developed as tumor biomarkers and therapeutic targets.However,the potential function of the small Cajal body-specific RNA(scaRNA)SCARNA16,a newly identified ncRNA,remains to be explored in HCC.Methods:In both HCC cell lines and specimens from 120 enrolled patients,the expression val-ues of SCARNA16 were detected.We divided patients into SCARNA16 high and low expression subgroups,and then analyzed the difference of various clinical characteristics and prognosis data between subgroups.Results:Compared to paired controls,SCARNA16 was significantly down-regulated in HCC cell lines and clinical specimens(p<0.01).Besides,HCC patients with lower SCARNA16 expression commonly presented with larger and more tumor lesions,more ves-sel carcinoma emboli,more capsular invasion and higher TNM stages(p<0.05).Moreover,SCARNA16 expression was negatively correlated with postoperative prognosis of HCC patients in 5-year follow-up,including tumor-free survival(TFS)(median time of low vs.high subgroups:14 vs.48 months,p=0.006)and overall survival(OS)(median time of low vs.high subgroups:39 vs.52 months,p=0.001).Besides,SCARNA16 acted as an independent prognostic bio-marker in TFS(hazard ratio[HR]:0.578,95%CI:0.345-0.969,p=0.038)and OS(HR:0.366,95%CI:0.178-0.752,p=0.006).Conclusions:Low expression patterns of SCAR-NA16 remarkably associated with severe clinical status and poor survival of patients,suggesting that SCARNA16 pos-sesses potency as a novel biomarker for HCC.
基金supported by the National Key R&D Program of China(2021YFA0909900)the National Natural Science Foundation of China(52173142,52233013)+1 种基金the“Pioneer”and“Leading Goose”R&D Program of Zhejiang(2024C03168)the Startup Package of Zhejiang University.
文摘The intricate tumor microenvironment presents formidable obstacles to the efficacy of adoptive T cell therapy in the management of solid tumors by limiting the infiltration and inducing exhaustion of the transferred T cells.Here,we developed a bacterial-based adjuvant approach that augments the efficacy of adoptive T-cell therapy for solid tumor treatment.Our study reveals that intratumor injection of E.coli MG1655 normalizes tumor vasculatures and reprograms tumor-associated macrophages into M1 phenotype that produce abundant CCL5,together facilitating tumor infiltration of adoptively transferred T cells.The depletion of tumor-associated macrophages or CCL5 neutralization in vivo leads to the significantly decreased solid tumor infiltration of adoptive T cells in the presence of bacteriotherapy.This combinatorial therapy,consisting of E.coli adjuvant and adoptive T-cell therapy,effectively eradicates early-stage melanoma and inhibits the progression of pancreatic tumors.Notably,this dual strategy also strengthened the distal tumor control capabilities of adoptive T-cell therapy through the induction of in situ tumor vaccination.This dual therapeutic approach involving bacterial therapy targeting the interior of solid tumors and adoptive T-cell therapy attacking the tumor periphery exhibits potent therapeutic efficacy in achieving the eradication of advanced-stage tumors,including melanoma and hepatocellular carcinoma,by converging attacks from both inside and outside the tumor tissues.
